Men who attended a structured yoga class twice a week during prostate cancer radiation treatment reported less fatigue and better sexual and urinary function than those who didn’t, according to a clinical trial led by the Perelman School of Medicine at the University of Pennsylvania. It is the first randomized trial to look at the effect of twice-weekly yoga on the side-effects and quality of life issues caused by prostate cancer treatment. The results published this week in the International Journal of Radiation Oncology, Biology, and Physics.

All of the patients in the trial underwent between six and nine weeks of external beam radiation therapy for prostate cancer. The patients were randomized into two groups:  one arm participated in a yoga class that met twice a week and the other arm served as a control group. Patients who already practiced yoga on their own were not eligible for the study, nor were patients with a history of prior radiation therapy or those with metastatic disease.

Only two instructors led classes for this study, with the lead instructor teaching 75 percent of the classes. Each session lasted 75 minutes, beginning with five minutes of breathing and centering techniques and ending with five minutes of Savasana, a common yoga position. Typical sessions incorporated sitting, standing, and reclining positions that were modified using props to adapt to each patient’s needs and restrictions.

Patients were primarily evaluated on their level of fatigue. Each man filled out a nine-item questionnaire assessing fatigue severity and impact on daily life.  The first questionnaire was given between two and three weeks before the start of radiotherapy, then twice a week while receiving radiotherapy, with a final survey filled out within a week of their last yoga class or last radiation treatment, depending on the assigned study arm.

“At their baseline, before patients started treatment, patients in both groups were on the lower end of the scale, meaning they reported lower amounts of fatigue,” said the trial’s principal investigator Neha Vapiwala, MD, an associate professor of Radiation Oncology. “But as treatment went on, we observed a difference in the two groups.”

Click here to view the full release.